HSPG2 and cancer: Since metabolic reprogramming in cancer cells is linked to the development of drug resistance [20], we first analyzed our previous RNA-sequencing data (GSE214990) to investigate the metabolic processes-regulated PLC pathway inhibition with U73122 in a Dex-resistant B-ALL cell line.